Metamark, Definiens to Combine Protein Detection, Image Analysis in Predictive, Prognostic Assays | GenomeWeb

In developing prognostic and predictive assays with the aid of Definiens' image analysis technologies, Metamark Genetics is hoping to advance personalized cancer care by capturing the heterogeneity within individual patients' tumors.

As part of a deal announced last week, Cambridge, Mass.-based Metamark's multiplex protein detection technology, called the Prognosis Determinant Discovery Platform, will be combined with Definiens' Developer XD and Tissue Studio image analysis software in an effort to advance cancer diagnostics.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.